MindBio Therapeutics Corp. Reports Six Month Sustained Antidepressant Response in Clinical Trials. 72% reduction in Depression Severity Recorded.
Dear ,
We are excited to share significant progress in our mission to transform mental health treatments. Six months after the completion of an 8-week treatment cycle with our lead candidate MB22001, follow up data demonstrates a sustained 72% reduction in depression severity, with 58% of patients experiencing complete remission from their depression.
Key Highlights:
Lasting Antidepressant Effects: Six months post-treatment, patients continue to experience substantial improvement in symptoms.
- 72% Overall Reduction in Depression symptoms.
- 58% Complete Remission from Depression
- Safety & Adherence: Patients self-administer at home, maintaining normal daily routines. No adverse events or serious side effects reported.
About MB22001
MB22001 is a proprietary self-titratable microdose formulation of lysergic acid diethylamide, designed for safe, at-home use. We are the only organisation conducting multiple Phase 2B trials government approved for take-home dosing of a psychedelic medicine in clinical trials, enabling participants to manage their treatment in real-world settings. Patients can take MB22001 and then get on with their day in the same way they would if they were taking any other medication.
Ongoing Trials
We currently have two Phase 2B trials underway, targeting depression and another trial targeting cancer-related depression symptoms, with a third Phase 2B trial focused on women’s health (PMS and PMDD) recently approved. These trials will run through 2025, and we are optimistic about the impact MB22001 can have on patients worldwide.
We are delighted that MB22001 demonstrates sustained antidepressant effects. This data brings us closer to our goal of offering an accessible, scalable treatment for depressive disorders. We believe MB22001 has the potential to redefine depression treatment for patients globally.
Thank you for supporting us as we work towards creating a brighter future for mental health.
JUSTIN HANKA
Chief Executive Officer & Co-Founder
MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)
Follow CEO Justin Hanka on LinkedIn:
https://www.linkedin.com/in/justinhanka/
Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true
0 comments